- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT03416907
Informed Consent Formats by Information Preference and Priority
Обзор исследования
Статус
Условия
Подробное описание
Тип исследования
Регистрация (Действительный)
Фаза
- Непригодный
Контакты и местонахождение
Места учебы
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Соединенные Штаты, 15213
- Carnegie Mellon University
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- 18 Years Old or Older
- Read and agreed to informed consent
- Indicated desire to participate
- Diagnosed with asthma
- US resident
Exclusion Criteria:
- Participants from whom we receive multiple responses will be dropped from analysis (but will be compensated for participation)
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Фундаментальная наука
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Одинокий
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Активный компаратор: Original
Participants will review the full-length, original consent form for the clinical trial.
|
Participants will review the full-length, original consent form for the clinical trial.
|
|
Экспериментальный: Shortened
Participants will review a shortened consent form for the clinical trial, which includes only material indicated as important by 2/3 of participants from a previous study.
|
Participants will review a shortened consent form for the clinical trial, which includes only material indicated as important by 2/3 of participants from a previous study.
|
|
Экспериментальный: Reordered
Participants will review a reordered, shortened consent form.
This form is based on the shortened consent form, but the sections are reordered based on a previous study, such that sentences previously rated as more likely to impact a participant's decision is more likely to be presented first (except for an initial introductory section).
|
Participants will review a reordered, shortened consent form.
This form is based on the shortened consent form, but the sections are reordered based on a previous study, such that sentences previously rated as more likely to impact a participant's decision is more likely to be presented first (except for an initial introductory section).
|
|
Экспериментальный: Highlighted
Participants will review a shortened consent form with a highlights box, where the highlights box includes the 10 sentences rates as most likely to impact a participant's decision from a previous study.
|
Participants will review a shortened consent form with a highlights box, where the highlights box includes the 10 sentences rates as most likely to impact a participant's decision from a previous study.
|
|
Экспериментальный: Interactive
Participants will review an interactive, shortened consent form, where hyperlinks to different sections of the consent form are provided.
The landing page includes the introductory section.
|
Participants will review an interactive, shortened consent form, where hyperlinks to different sections of the consent form are provided.
The landing page includes the introductory section.
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Score for high impact questions
Временное ограничение: through study completion, an average of 30 minutes
|
Sum of correct answers (T/F) for any item relating to material that was rated as 50 or higher on impact on willingness to enroll in a previous study.
|
through study completion, an average of 30 minutes
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Score for low impact questions
Временное ограничение: through study completion, an average of 30 minutes
|
Sum of correct answers (T/F) for any item relating to material that was rated as 49 or lower on impact on willingness to enroll in a previous study.
|
through study completion, an average of 30 minutes
|
|
Total score for all questions
Временное ограничение: through study completion, an average of 30 minutes
|
Sum of correct answers (T/F) on full knowledge test.
|
through study completion, an average of 30 minutes
|
|
Interaction effect of format and importance on likelihood of correct answer
Временное ограничение: through study completion, an average of 30 minutes
|
Interaction effect in a logistic regression predicting a correct answer, based on the format of the consent form and the importance of the answer.
|
through study completion, an average of 30 minutes
|
|
Scores for different information categories
Временное ограничение: through study completion, an average of 30 minutes
|
Sum of correct answers (T/F) for each of the 20 information categories
|
through study completion, an average of 30 minutes
|
|
Effect of location on score
Временное ограничение: through study completion, an average of 30 minutes
|
Logistic regression coefficient of likelihood of predicting a correct answer, based upon the location on which the sentence appeared--uses only the shortened, and the reordered conditions.
Note that sentences appearing in the introduction (which is the first section of all treatments) must be dropped, as there will be no variation in location.
|
through study completion, an average of 30 minutes
|
|
Decision to enroll
Временное ограничение: through study completion, an average of 30 minutes
|
Likert measure of participants hypothetical decision to enroll in the study
|
through study completion, an average of 30 minutes
|
|
Confidence in enrollment decision
Временное ограничение: through study completion, an average of 30 minutes
|
Likert measure of participants confidence in hypothetical decision to enroll in the study
|
through study completion, an average of 30 minutes
|
|
Satisfaction with consent structure
Временное ограничение: through study completion, an average of 30 minutes
|
Likert measure of participants satisfaction with the consent form
|
through study completion, an average of 30 minutes
|
|
Perception of investigator concern for well being
Временное ограничение: through study completion, an average of 30 minutes
|
Likert measure of participants belief in the investigator's concerns for the participant's well-being
|
through study completion, an average of 30 minutes
|
|
Perception of investigator transparency
Временное ограничение: through study completion, an average of 30 minutes
|
Likert measure of participants belief that the investigator is trying to communicate information about the trial accurately
|
through study completion, an average of 30 minutes
|
|
Participant's probability estimate of the likelihood that the treatment would help control their asthma
Временное ограничение: through study completion, an average of 30 minutes
|
Survey question of the following form: 'If you enrolled in the trial described in the consent form, what is the probability that the treatment could help control your asthma better, where 0% means "no chance at all of helping" and 100% means "would definitely help"?' Participants provided with drop-down menu including values from 0% to 100% in increments of 1%. |
through study completion, an average of 30 minutes
|
Другие показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Participant's free-response text describing what was learned from reading the informed consent document
Временное ограничение: through study completion, an average of 30 minutes
|
Survey question of the following form: "What are some of the key things you learned from reading the informed consent document?" Participants are then provided with an free-response text box where they are allowed to enter whatever text they want, as long as they enter some text. These responses will be coded by two independent coders, blinded to the treatment arms, using an emergent coding system to identify different topics that participants may raise. |
through study completion, an average of 30 minutes
|
Соавторы и исследователи
Спонсор
Соавторы
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Другие идентификационные номера исследования
- STUDY2017_00000268
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .
Клинические исследования Original consent form
-
University of FloridaEunice Kennedy Shriver National Institute of Child Health and Human Development... и другие соавторыЗавершенныйКоммуникационные исследования | Отношение медицинского персонала | Доверять | Отношение к компьютерам | Отношения между исследователем и субъектомСоединенные Штаты
-
Bio-Strath AGZentrum für Adipositas- und Stoffwechselmedizin Winterthur GmbHЗавершенныйИзбыточный весШвейцария
-
Radicle ScienceЗавершенныйЗдоровье желудочно-кишечного трактаСоединенные Штаты
-
Ottawa Hospital Research InstituteРекрутинг
-
Mike O'Callaghan Military HospitalЗавершенный
-
Mayo ClinicЗавершенныйКритически боленСоединенные Штаты
-
Mike O'Callaghan Military HospitalЗавершенный
-
SymateseАктивный, не рекрутирующий
-
East Kent Hospitals University NHS Foundation TrustЗавершенныйCOVID-19Соединенное Королевство
-
Jules Bordet InstituteRoche Pharma AGПрекращено